Heart failure & cardiomyopathies
Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction
Authors' conclusion
In this cohort of patients with HFpEF, arterial 15-keto PGF2a, a stable metabolite of PGF2a, significantly predicted 5-year mortality.
Study context
- Population
- Heart failure with preserved ejection fraction (HFpEF) patients undergoing right heart catheterization
- Participants
- 90 patients
- Exposure
- Elevated vs non-elevated arterial 15-keto prostaglandin F2a (PGF2a)
- Outcome
- Mortality
- Follow-up
- 5 years
Methodological detailssingle-centre, 143 arterial and 143 venous oxylipins measured by liquid chromatography-mass spectrometry
- Single-centre
- 143 arterial and 143 venous oxylipins measured by liquid chromatography-mass spectrometry
Main finding
As reported in the abstract
5-year mortality, arterial 15-keto PGF2a
15-keto PGF2a as predictor of 5-year mortality, multivariable adjusted OR (CI)
OR 1.82; CI 1.03, 3.5
Observational data: associations, not effects.
Further findings
Baseline characteristics of patients with 5-year mortality
- Increased age, decreased BMI, decreased DBP, worse renal function, more severe pulmonary hypertension and right heart dysfunction
Original publication
Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction. ESC Heart Fail. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →